The {pharmaceutical industry is currently exploring alternative treatment approaches for obesity , and the arrival of semaglutide 10mg vials represents a significant development . Clinicians are beginning to evaluate the possible benefits and risks associated with this increased potency version , notably in relation to existing standard semaglutide